

# AP4 deficiency

## A novel form of neurodegeneration with brain iron accumulation?

Agathe Roubertie, MD, PhD, Nelson Hieu, MSc,\* Charles-Joris Roux, MD,\* Nicolas Leboucq, MD, Gael Manes, PhD, Majida Charif, PhD, Bernard Echenne, MD, Cyril Goizet, MD, PhD, Claire Guissart, PhD, Pierre Meyer, MD, Cecilia Marelli, MD, François Rivier, MD, PhD, Lydie Burglen, MD, Rita Horvath, MD, PhD, Christian P. Hamel, MD, PhD, and Guy Lenaers, PhD

### Correspondence

Dr. Roubertie  
a-roubertie@chu-montpellier.fr

*Neurol Genet* 2018;4:e217. doi:10.1212/NXG.000000000000217

## Abstract

### Objective

To describe the clinico-radiological phenotype of 3 patients harboring a homozygous novel *AP4M1* pathogenic mutation.

### Methods

The 3 patients from an inbred family who exhibited early-onset developmental delay, tetraparesis, juvenile motor function deterioration, and intellectual deficiency were investigated by magnetic brain imaging using T1-weighted, T2-weighted, T2\*-weighted, fluid-attenuated inversion recovery, susceptibility weighted imaging (SWI) sequences. Whole-exome sequencing was performed on the 3 patients.

### Results

In the 3 patients, brain imaging identified the same pattern of bilateral SWI hyposignal of the globus pallidus, concordant with iron accumulation. A novel homozygous nonsense mutation was identified in *AP4M1*, segregating with the disease and leading to truncation of half of the *adap* domain of the protein.

### Conclusions

Our results suggest that *AP4M1* represents a new candidate gene that should be considered in the neurodegeneration with brain iron accumulation (NBIA) spectrum of disorders and highlight the intersections between hereditary spastic paraplegia and NBIA clinical presentations.

\*These authors contributed equally to this work.

From the Département de Neuropédiatrie (A.R., B.E., P.M., F.R.), CHU Gui de Chauliac, Montpellier; Institut des Neurosciences de Montpellier (A.R., N.H., G.M., C.P.H.), INSERM U1051, Université de Montpellier; Service de Neuroradiologie (C.-J.R., N.L.), CHU Gui de Chauliac, Montpellier; Equipe MitoLab (M.C., G.L.), UMR CNRS 6015-INSERM 1083, Institut MitoVasc, University of Angers, France; Department of Medical Genetics (C. Goizet), Hôpital Pellegrin, Bordeaux University Hospital; MRGM Laboratory (C. Goizet), INSERM U1211, University of Bordeaux; Laboratoire de Génétique Moléculaire (C. Guissart), CHU de Montpellier; U1046 INSERM (P.M., F.R.), UMR9214 CNRS, Université de Montpellier; Department of Neurology (C.M.), University Hospital Gui de Chauliac, Montpellier; Centre de Référence des Malformations et Maladies Congénitales du Cervelet (L.B.), Service de Génétique, Hôpital Armand Trousseau, AP-HP, Paris, France; Wellcome Trust Centre for Mitochondrial Research (R.H.), Institute of Genetic Medicine, Newcastle University, United Kingdom; and Centre of Reference for Genetic Sensory Diseases (C.P.H.), Montpellier, France.

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/NG](http://Neurology.org/NG).

The Article Processing charge was funded by the Montpellier Hospital.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

## Glossary

**HSP** = hereditary spastic paraplegia; **NBIA** = neurodegeneration with brain iron accumulation; **SWI** = susceptibility weighted imaging; **WES** = whole-exome sequencing.

Hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurodegenerative diseases clinically characterized by progressive lower extremity weakness and spasticity, which may be isolated (pure HSP) or combined with other neurologic or nonneurological signs (complex HSP).<sup>1,2</sup> More than 70 genes have been implicated, emphasizing diverse molecular pathogenic mechanisms.<sup>3</sup> In this respect, recessive mutations in genes encoding the different subunits of adaptor protein complex-4, (*AP4B1*, *AP4M1*, *AP4E1*, and *AP4S1*) have been identified in patients with complex HSP (*SPG 47*, *50*, *51*, and *52* respectively).<sup>4–8</sup> The AP4-deficiency syndrome is characterized by progressive spasticity, microcephaly, intellectual deficiency, dysmorphic traits, and growth retardation,<sup>4–8</sup> while epilepsy and peripheral neuropathy might be associated.<sup>4,9</sup> Brain imaging phenotypes reported up to now are characterized by cerebral atrophy, asymmetric enlargement of lateral ventricles, white matter loss, and thin corpus callosum splenium.<sup>8–10</sup> Thin and globoid hippocampal cortex<sup>9</sup> and tortuosity of intraextracranial large vessels were also reported.<sup>4</sup>

Neurodegeneration with brain iron accumulation (NBIA), which is characterized by dystonia, parkinsonism, spasticity, and brain iron accumulation on MRI, represents another inherited group of neurodegenerative disorders, due to mutations in 10 genes, with molecular overlaps with HSP.<sup>11,12</sup>

Here, we report 3 patients from the same kindred who harbor a homozygous *AP4M1* mutation. They exhibit the typical clinico-radiological phenotype of AP4-deficiency syndrome, but surprisingly associated with bilateral pallidal iron accumulation on brain imaging, thus establishing a link between AP4-related complex HSP and NBIA disorders.

## Methods

### Standard protocol approvals, registrations, and patient consents

The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethical committee. Written informed consent was obtained from the patients' legal representatives.

### Whole-exome sequencing and brain imaging

Whole-exome sequencing (WES) was performed on the DNA from the 3 affected patients by Aros Ltd. Homozygous mutations common to the 3 patients were filtered progressively for their frequency (<1%), alteration of the open reading frame (frameshift, splicing, missense, and nonsense mutations), and ultimately for their localization in the

homozygous regions common to the 3 patients. Sanger sequencing allowed for their confirmation and segregation study in the family.

CT was performed on a 64-section CT scanner (Discovery750 HD; GE Health care, Milwaukee, WI). MRIs were acquired on a 1.5-T system (AVENTO; Siemens medical solutions, Erlangen, Germany) as follows: axial slices T2-weighted, T2\*-weighted, fluid-attenuated inversion recovery, susceptibility weighted imaging (SWI) sequences, and sagittal slices T1-weighted sequences.

## Results

### Clinical data

The clinical features of the 3 patients originating from a large consanguineous Moroccan family (figure 1A) are described in table. Psychomotor retardation with spasticity of the 4 limbs was noticed early in life. Clinical examination from the first year showed spastic tetraplegia, with pyramidal tract signs and equinovarus. Patients IV-2 and IV-5 sat unaided at 7 months; patient IV-2 was able to crawl at 2 years but never managed to walk; her sister IV-5 could walk short distances with unsteady spastic gait from the age of 5 years. Patient IV-7 sat unaided at 11 months of age and walked at 3 years, with a broad-based unsteady gait. The patients exhibited stable severe mental deficiency, without behavioral disturbance. Motor achievements progressively deteriorated at adolescence, with loss of the highest motor skills, but without additional cognitive decline; from that time, bradykinesia, hypomimic, drooling, and athetoid movements of the hands were also noticed. Patients IV-5 and IV-7 displayed short stature. Dysmorphic features (figure 2, Aa, Ba, Ca) were also present. The 3 patients needed assistance to most common daily living activities.

The following investigations were normal: electromyoneurography recording, cardiac ultrasound scan, visual and auditory evoked potentials, fundus examination, karyotype analysis on lymphocytes (cases IV-2, IV-5 and IV-7), *PANK2* and *PLA2G6* Sanger sequencing (patient IV-7), and analyses of mitochondrial enzymatic activities on a muscle sample (patient IV-2).

### Genetic results

Comparison of WES results performed for patients IV-2, IV-5, and IV-7 revealed 3 homozygous regions, 1 on chromosome 7 (5.7 Mb) and 2 on chromosome 9 (2.25 and 1.31 Mb). A total of 14,753 exonic variants were common to the 3 patients, and by progressively filtering them, we identified 4,974

**Table** Clinical features of 3 *AP4M1* individuals

Patient	Patient IV-2	Patient IV-5	Patient IV-7
Sex/age at last examination	F/25 y	F/16 y	F/23 y
Perinatal parameter	Normal	Normal	Low birth weight
Seizures	No	1 febrile seizure during the second year of life	1 febrile seizure at 20 m
Age at acquisition of unaided sitting	7 m	7 m	11 m
Highest motor achievements	Able to crawl at 2 y	Unsteady spastic gait at 5 y	Independent broad-based unsteady gait at 3 y
Motor deterioration/age	Unable to crawl at 13 y	Assisted gait from 12 y	Assisted gait from 15 y
Spasticity and pyramidal tract signs	Yes	Yes	Yes
Equinovarus	Yes	Yes	Yes
Bradykinesia and athetoid movements of the hands	From adolescence	From adolescence	From adolescence
Language	Short sentences	Short sentences	Less than 10 words
Behavior	Shy and introverted form adolescence	Normal	Smiley
Intellectual deficiency	Severe	Moderate	Severe
Growth parameter at last follow-up	Normal	Short stature	Short stature
	Height 160 cm, weight 68 kg	Height 150 cm, weight 55 kg	Height 143 cm, weight 44 kg
Microcephaly	No	No	Yes
Head circumference	53 cm	52 cm	48.5 cm
Dysmorphism	Yes	Yes	Yes

m = month; y = year.

homozygous variants, among which 2,546 were non-synonymous, frameshift, splicing, or stop variants. Further filtering for damaging variants with a frequency lower than 1% identified 3 mutations in the *AP4M1*, *HRNR*, and *NPIPL3* genes, but only the 1 in *AP4M1* was located in chromosome 7, in 1 of the 3 homozygous regions.

This c.916C>T mutation (rs369459721) is leading to a premature stop codon (p.R306X), truncating the last 147 residues of the protein (figure 1, B and C). It has a global allelic frequency of  $2.4 \times 10^{-5}$  in the ExAC and a frequency of  $3.0 \times 10^{-5}$  in Non-Finnish European and  $9.3 \times 10^{-5}$  in African, while it was not encountered in the rest of the world.

Analysis of the homozygous variants located in the 10 known NBIA genes revealed 2 common variants, located in *CP* (rs701753) and *PANK* (rs3737084), but they were not damaging, had a frequency higher than 1%, and were located away from the 3 homozygous regions.

### Brain imaging


Brain MRI of the 3 patients showed global cerebral atrophy, white matter loss, asymmetric ventriculomegaly (figure 2, B, E, and H), and thinning of the splenium of the corpus

callosum (data not shown J). T1 sequences showed an iso-intense pattern of the globus pallidus (data not shown). T2 sequences revealed symmetric mild hypointensity of the globus pallidus, which was significantly accentuated on SWI sequences (figure 2, Ab, Ac, Bb, Bc, Cb, Cc, D). Patient IV-7's CT was normal (data not shown).

## Discussion

We identified a homozygous nonsense mutation in *AP4M1* in 3 women from the same inbred family by WES. This R306X mutation deletes the last 147 residues of the protein, truncating half of the *adap* domain, an effect similar to that reported in 2 other families who harbored a stop codon truncating the *AP4M1* protein at positions 318 and 338.<sup>9</sup> Until now, only 5 different *AP4M1* mutations have been reported in 7 families with a common clinical presentation<sup>4,5,9,13-15</sup> (figure 1C). The 3 patients from our study share the same clinical phenotype with variable severity, consisting in early-onset developmental delay, tetraparesis, juvenile motor function deterioration, intellectual deficiency, athetoid upper limb movements, bradykinesia, and mild dysmorphism, which fits with the previously described *AP4*-deficiency syndrome. Even if the bilateral pallidal

**Figure 1** Identification of a novel *AP4M1* mutation



(A) Pedigree showing the segregation of the *AP4M1* c.916C>T (p.R306X) mutation in the family; black symbols indicate affected patients. (B) Electrophoregrams showing the wild-type (top), the homozygous mutated (middle), and heterozygous (bottom) sequence of *AP4M1*. (C) Localization of *AP4M1* mutations in the protein: the structure of the *AP4M1* protein (domain and amino acid positions) is described with all the pathogenic missense mutations<sup>5,14</sup> (green), nonsense mutation<sup>9,15</sup> (violet), frameshift<sup>4,13</sup> (pink flag) mutations reported to date (in black), and in the present cases (in red). HM = homozygous; HT = heterozygous; WT = wild type.

hyposignal is mild on T2 sequences and could be interpreted as physiologic iron accumulation at this age, the substantial hyposignal on SWI is totally unusual in patients of the same age. These findings, correlated with the absence of hypersignal on T1-weighted imaging or CT hyperdensities in the patients, are strongly suggestive of brain iron overload.

Iron deposits have not been previously reported in patients with AP4-deficiency syndrome. Nevertheless, magnetic susceptibility sequences, which can confirm the presence of iron, have not been performed in most of the reported cases; therefore, this feature might have been underdiagnosed. A search for homozygous mutations common to the 3 patients in the 10 published NBIA genes revealed 2 variants located in *PANK* and *CP*, but their frequency and the absence of pathogenicity were somehow incompatible with their involvement as modifier mutations switching HSP clinical presentation to NBIA.

Of interest, a patient with *AP4E1* mutations, whose brain MRI showed bilateral T2-hypointensity of the globus pallidus, has already been described.<sup>8</sup> This peculiar finding, although not discussed in the article, strongly suggests iron accumulation in this *AP4E1* patient, as in our 3 *AP4M1* patients.

The pathophysiology of HSP involves many cellular pathways as cellular transport, nucleotide metabolism, and synapse and axon developments, providing a causative link


between HSP and other neurodegenerative diseases.<sup>3,16</sup> Overlaps between HSP and NBIA are well known, as already reported for cases with mutations in *FA2H* and *C19orf12* genes (SPG 35 and 43, respectively).<sup>11,17</sup> The AP-4 complex is a heterotetramer ubiquitously expressed in the CNS early in the embryologic and postnatal development and is implicated in vesicle formation, post-Golgi protein trafficking, and sorting processes.<sup>18</sup> Eventually, AP-4 dysfunction might affect autophagy by disrupting the early steps of endosomal formation, a process shared with Kufor-Rabeb disease and beta-propeller protein-associated neurodegeneration, 2 forms of NBIA related to *ATP13A2* and *WDR45* genes, respectively.<sup>11,12</sup>

Moreover, NBIA disorders are probably underdiagnosed, and the evolution of technologies and practices in radiology leads to the identification of many new candidate genes through the incorporation of susceptibility weighted sequences more frequently in the brain imaging protocols.<sup>19</sup> Our study has limitations, especially because of the small sample size.

Nevertheless, according to our findings in *AP4M1* mutated patients, we recommend that brain MRI with susceptibility weighted sequences be included in the brain imaging protocol for patients with suspected HSP and AP4-deficiency syndrome to collect a larger group of patients, and we propose



**Figure 2** Facial appearance and brain imaging



(A) Patient IV-2, 25 years. (B) Patient IV-5, 16 years. (C) Patient IV-7, 23 years. (D) Control, 20 years. (A.a, B.a, and C.a) Photographs showing dysmorphism, with bulbous nose, broad nasal bridge, coarse features, and wide-open mouth. (A.b, B.b, and C.b) Axial T2-weighted sequence showing asymmetric ventriculomegaly (black stars) and mild hypointense aspect of the globus pallidus (arrows). Diffuse brain atrophy and loss of white matter without signal abnormality, particularly in occipito parietal areas, are also observed. (A.c, B.c, C.c, and D) Axial susceptibility weighted imaging sequence showing bilateral intense hyposignal of the globus pallidus, significantly predominant in their medial part (arrows, A.c, B.c, and C.c) compared with the control (D).

that mutations in *AP4* genes be considered and screened in a subset of patients with NBIA spectrum disorders.

### Author contributions

Design or conceptualization of the study: Agathe Roubertie, Christian P. Hamel, and Guy Lenaers. Analysis or interpretation of the data: Charles-Joris Roux, Nicolas Leboucq, Gael Manes, Majida Charif, Bernard Echenne, Cyril Goizet, Claire Guissart, Pierre Meyer, Cecilia Marelli, François Rivier, Lydie Burglen, and Rita Horvath. Drafting or revising the manuscript for intellectual content: Agathe Roubertie, Charles-Joris Roux, Cyril Goizet, and Guy Lenaers.

### Acknowledgment

The authors acknowledge the patients and their families for participating in the study. They thank La Fondation Maladies Rares et Retina France. They are indebted to the INSERM and CNRS and the Montpellier University for their

institutional supports. They thank the Region Pays de la Loire, Angers Loire-Métropole, University of Angers, and University Hospital of Angers for their support to the PREMMI project. They are indebted to Dr. Lagavulin for helpful discussions.

### Study funding

No targeted funding reported.

### Disclosure

A. Roubertie, N. Hieu, C.-J. Roux, N. Leboucq, G. Manes, M. Charif, and B. Echenne report no disclosures. C. Goizet has served on the scientific advisory boards of Amicus Therapeutics and Sanofi Genzyme and has received travel funding/speaker honoraria from Sanofi Genzyme, Amicus Therapeutics, and Shire. C. Guissart and P. Meyer report no disclosures. C. Marelli has received travel funding/speaker honoraria from Actelion Pharmaceuticals. F. Rivier, L. Burglen, and

R. Horvath report no disclosures. C.P. Hamel is deceased; disclosures are not included for this author. G. Lenaers reports no disclosures. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/NG](http://Neurology.org/NG).

Received September 16, 2017. Accepted in final form December 10, 2017.

## References

1. Finsterer J, Löscher W, Quasthoff S, Wanschitz J, Auer-Grumbach M, Stevanin G. Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. *J Neurol Sci* 2012;318:1–18.
2. Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. *Acta Neuropathol* 2013;126:307–328.
3. Kara E, Tucci A, Manzoni C, et al. Genetic and phenotypic characterization of complex hereditary spastic paraplegia. *Brain* 2016;139:1904–1918.
4. Verkerk AJ, Schot R, Dumee B, et al. AR ticle mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy. *Am J Hum Genet* 2009;85:40–52.
5. Jameel M, Klar J, Tariq M, et al. A novel AP4M1 mutation in autosomal recessive cerebral palsy syndrome and clinical expansion of AP-4 deficiency. *BMC Med Genet* 2014;15:1–7.
6. Jamra RA, Philippe O, Raas-Rothschild A, et al. Adaptor protein complex 4 deficiency causes severe autosomal-recessive intellectual disability, progressive spastic paraplegia, shy character, and short stature. *Am J Hum Genet* 2011;88:788–795.
7. Abdollahpour H, Alawi M, Kortüm F, et al. An AP4B1 frameshift mutation in siblings with intellectual disability and spastic tetraplegia further delineates the AP-4 deficiency syndrome. *Eur J Hum Genet* 2014;23:256–259.
8. Moreno-De-Luca A, Helmers SL, Mao H, et al. Adaptor protein complex-4 (AP-4) deficiency causes a novel autosomal recessive cerebral palsy syndrome with microcephaly and intellectual disability. *J Med Genet* 2011;48:141–144.
9. Tüysüz B, Bilguvar K, Koçer N, et al. Autosomal recessive spastic tetraplegia caused by AP4M1 and AP4B1 gene mutation: expansion of the facial and neuroimaging features. *Am J Med Genet A* 2014;164:1677–1685.
10. Blumkin L, Lerman-Sagie T, Lev D, Yosovich K, Leshinsky-Silver E. A new locus (SPG47) maps to 1p13.2-1p12 in an Arabic family with complicated autosomal recessive hereditary spastic paraplegia and thin corpus callosum. *J Neurol Sci* 2011;305:67–70.
11. Arber CE, Li A, Houlden H, Wray S. Review: insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. *Neuropathol Appl Neurobiol* 2015;42:220–241.
12. Meyer E, Kurian MA, Hayflick SJ. Neurodegeneration with brain iron accumulation: genetic diversity and pathophysiological mechanisms. *Annu Rev Genomics Hum Genet* 2015;16:257–279.
13. Languouët M, Siquier-Pernet K, Sanquer S, et al. Contiguous mutation syndrome in the era of high-throughput sequencing. *Mol Genet Genomic Med* 2015;3:215–220.
14. Najmabadi H, Hu H, Garshasbi M, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* 2011;478:57–63.
15. Duerinckx S, Verhelst H, Perazzolo C, et al. Severe congenital microcephaly with AP4M1 mutation, a case report. *BMC Med Genet* 2017;18:48.
16. Novarino G, Fenstermaker AG, Zaki MS, et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. *Science* 2014;343:506–511.
17. Landouré G, Zhu PP, Lourenco CM, et al. Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12. *Hum Mutat* 2013;34:1357–1360.
18. Simmen T, Höning S, Icking A, Tikkanen R, Hunziker W. AP-4 binds basolateral signals and participates in basolateral sorting in epithelial MDCK cells. *Nat Cell Biol* 2002;4:154–159.
19. Herebian D, Alhaddad B, Seibt A, et al. Coexisting variants in OSTM1 and MANEAL cause a complex neurodegenerative disorder with NBIA-like brain abnormalities. *Eur J Hum Genet* 2017;25:1–4.

# Neurology<sup>®</sup> Genetics

## AP4 deficiency: A novel form of neurodegeneration with brain iron accumulation?

Agathe Roubertie, Nelson Hieu, Charles-Joris Roux, et al.

*Neurol Genet* 2018;4;

DOI 10.1212/NXG.0000000000000217

**This information is current as of January 24, 2018**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://ng.neurology.org/content/4/1/e217.full.html">http://ng.neurology.org/content/4/1/e217.full.html</a>
<b>References</b>	This article cites 19 articles, 2 of which you can access for free at: <a href="http://ng.neurology.org/content/4/1/e217.full.html##ref-list-1">http://ng.neurology.org/content/4/1/e217.full.html##ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Genetics</b> <a href="http://ng.neurology.org/cgi/collection/all_genetics">http://ng.neurology.org/cgi/collection/all_genetics</a> <b>Developmental disorders</b> <a href="http://ng.neurology.org/cgi/collection/developmental_disorders">http://ng.neurology.org/cgi/collection/developmental_disorders</a> <b>MRI</b> <a href="http://ng.neurology.org/cgi/collection/mri">http://ng.neurology.org/cgi/collection/mri</a> <b>Spastic paraplegia</b> <a href="http://ng.neurology.org/cgi/collection/spastic_paraplegia">http://ng.neurology.org/cgi/collection/spastic_paraplegia</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://ng.neurology.org/misc/about.xhtml#permissions">http://ng.neurology.org/misc/about.xhtml#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://ng.neurology.org/misc/addir.xhtml#reprintsus">http://ng.neurology.org/misc/addir.xhtml#reprintsus</a>

*Neurol Genet* is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.

